ALIMライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:37):

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally...

Stats
本日の出来高	14 340.00
平均出来高	71 925.00
時価総額	189.52M
EPS	$0 ( 2024-03-07 )
次の収益日	( $-0.0400 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.31
ATR14	$0.0210 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Ashman Philip	Sell	12 103	Common Stock
2024-03-11	Werner Jason M.	Buy	1 800	Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Performance-Based Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Restricted Stock Units
2024-03-11	Eiswirth Richard S Jr	Buy	14 700	Restricted Stock Units

INSIDER POWER
27.01
Last 77 transactions
Buy: 33 555 909 \| Sell: 20 075 544

ボリューム相関

長: 0.09 (neutral)

短: -0.12 (neutral)

Signal:(52.237) Neutral

Alimera Sciences Inc 相関

10 最も正の相関
ADV	0.943
RCMT	0.942
BTWN	0.941
AMZN	0.933
USLM	0.933
KE	0.93
RXST	0.929
HUSN	0.928
MRAM	0.928
ALTO	0.928

10 最も負の相関
AKU	-0.948
IMBI	-0.942
AMRB	-0.936
RMBS	-0.93
STRM	-0.928
AGRI	-0.927
ENNV	-0.924
LOPE	-0.923
EYEN	-0.921
PTMN	-0.919

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Alimera Sciences Inc 相関 - 通貨/商品

0.30
( neutral )

0.33
( neutral )

0.00
( neutral )

0.46
( neutral )

-0.36
( neutral )

-0.38
( neutral )

Alimera Sciences Inc 財務諸表

Annual	2023
収益:	$80.75M
総利益:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2023
収益:	$80.75M
総利益:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2022
収益:	$54.13M
総利益:	$46.15M (85.26 %)
EPS:	$-2.59

FY	2021
収益:	$59.03M
総利益:	$52.00M (88.09 %)
EPS:	$-0.854

Financial Reports:

No articles found.

Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.